AEB071
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uveal Melanoma
Conditions
Uveal Melanoma
Trial Timeline
Dec 20, 2011 → May 22, 2019
NCT ID
NCT01430416About AEB071
AEB071 is a phase 1 stage product being developed by Novartis for Uveal Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01430416. Target conditions include Uveal Melanoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01430416 | Phase 1 | Completed |
| NCT01402440 | Phase 1 | Terminated |
| NCT00615693 | Phase 2 | Completed |
| NCT00545259 | Phase 1 | Completed |
| NCT00492869 | Phase 1/2 | Completed |
| NCT00416546 | Phase 1 | Completed |
| NCT00409929 | Phase 1 | Completed |
Competing Products
20 competing products in Uveal Melanoma